Peter Brian Bach

Peter Brian Bach's AcademicInfluence.com Rankings

Peter Brian Bach

Medical

#2742

World Rank

#3175

Historical Rank

Public Health

#419

World Rank

#433

Historical Rank

Epidemiology

#518

World Rank

#540

Historical Rank

medical Degrees

Peter Brian Bach

Philosophy

#7827

World Rank

#11091

Historical Rank

Logic

#4861

World Rank

#6193

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Peter Brian Bach Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Peter Brian Bach's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population (2002) (1716)
Benefits and harms of CT screening for lung cancer: a systematic review. (2012) (1076)
A Paradigm Shift in U.S. Breast Reconstruction: Increasing Implant Rates (2013) (739)
The influence of hospital volume on survival after resection for lung cancer. (2001) (678)
Racial differences in the treatment of early-stage lung cancer. (1999) (577)
Primary care physicians who treat blacks and whites. (2004) (573)
Variations in lung cancer risk among smokers. (2003) (560)
Variations in morbidity after radical prostatectomy. (2002) (542)
Care patterns in Medicare and their implications for pay for performance. (2007) (522)
Age and adjuvant chemotherapy use after surgery for stage III colon cancer. (2001) (510)
Influence of hospital procedure volume on outcomes following surgery for colon cancer. (2000) (486)
Computed tomography screening and lung cancer outcomes. (2007) (463)
NCCN Task Force Report: Oral chemotherapy. (2008) (396)
Survival of blacks and whites after a cancer diagnosis. (2002) (394)
Pricing in the Market for Anticancer Drugs (2014) (384)
Limits on Medicare's ability to control rising spending on cancer drugs. (2009) (377)
The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. (2004) (372)
Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. (2013) (368)
Hospital and Surgeon Procedure Volume as Predictors of Outcome Following Rectal Cancer Resection (2002) (342)
Rapid-learning system for cancer care. (2010) (325)
The Effect of Clustering of Outcomes on the Association of Procedure Volume and Surgical Outcomes (2003) (315)
Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Summary and Appraisal of Published Evidence (2001) (296)
Delivery of preventive services to older adults by primary care physicians. (2005) (288)
Patient Demographic and Socioeconomic Characteristics in the SEER-Medicare Database: Applications and Limitations (2002) (273)
Lung cancer in US women: a contemporary epidemic. (2004) (271)
Screening for lung cancer: a review of the current literature. (2003) (259)
Outcomes after long-term acute care. An analysis of 133 mechanically ventilated patients. (1999) (258)
Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection (2003) (247)
Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. (2002) (242)
Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. (2013) (233)
Resurrecting treatment histories of dead patients: a study design that should be laid to rest. (2004) (228)
Primary Care Physicians' Links to Other Physicians Through Medicare Patients: The Scope of Care Coordination (2009) (223)
Survivorship care plans in research and practice (2012) (223)
Management of acute exacerbations of COPD: a summary and appraisal of published evidence. (2001) (223)
Overview of the SEER-Medicare Data (2002) (188)
The epidemiology and costs of chronic critical illness. (2002) (178)
Clinical prediction rule for atrial fibrillation after coronary artery bypass grafting. (2004) (174)
Components necessary for high-quality lung cancer screening: American College of Chest Physicians and American Thoracic Society Policy Statement. (2015) (169)
Physician visits prior to treatment for clinically localized prostate cancer. (2010) (164)
Cancer's next frontier: addressing high and increasing costs. (2010) (158)
Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare. (2001) (155)
Adherence to surveillance among patients with superficial bladder cancer. (2003) (133)
Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (2017) (132)
FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug. (2017) (131)
Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). (2007) (130)
Bilateral Mastectomy versus Breast-Conserving Surgery for Early-Stage Breast Cancer: The Role of Breast Reconstruction (2015) (113)
Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. (2013) (112)
Pack‐years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer (2010) (112)
The Influence of Sociodemographic Factors and Hospital Characteristics on the Method of Breast Reconstruction, Including Microsurgery: A U.S. Population–Based Study (2012) (111)
A Decade of Mortality Reductions in Major Oncologic Surgery: The Impact of Centralization and Quality Improvement (2010) (106)
Indication-specific pricing for cancer drugs. (2014) (105)
Overspending driven by oversized single dose vials of cancer drugs (2016) (101)
Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation. (2001) (100)
Screening for lung cancer: the guidelines. (2003) (97)
How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. (2010) (95)
Hospital volume, complications, and cost of cancer surgery in the elderly. (2015) (95)
Geographic Access and the Use of Screening Mammography (2010) (94)
Prevalence and Risk Factors for Symptomatic Thromboembolic Events after Shoulder Arthroplasty (2006) (91)
Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage. (2015) (91)
When the Average Applies to No One: Personalized Decision Making About Potential Benefits of Lung Cancer Screening (2012) (88)
Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. (2005) (86)
State expenditures for tobacco-control programs and the tobacco settlement. (2002) (81)
The Association between Hospital Volume and Total Shoulder Arthroplasty Outcomes (2005) (73)
Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs. (2015) (72)
Validation of a model of lung cancer risk prediction among smokers. (2006) (71)
A map to bad policy--hospital efficiency measures in the Dartmouth Atlas. (2010) (67)
Translating genomics in cancer care. (2013) (66)
Episode-based payment for cancer care: a proposed pilot for Medicare. (2011) (63)
Predicting mortality in patients suffering from prolonged critical illness: an assessment of four severity-of-illness measures. (2001) (63)
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. (2013) (62)
Fragmentation of Care for Frequently Hospitalized Urban Residents (2006) (62)
Outcomes and resource utilization for patients with prolonged critical illness managed by university-based or community-based subspecialists. (1998) (62)
New Math on Drug Cost-Effectiveness. (2015) (62)
Bronchiolitis obliterans organizing pneumonia in cancer: a case series. (2002) (60)
Is our natural-history model of lung cancer wrong? (2008) (60)
A prognostic model for 6-month mortality in elderly survivors of critical illness. (2011) (57)
Value-Based Pricing for Drugs: Theme and Variations. (2018) (57)
Cost consequences of the 340B drug discount program. (2013) (56)
Potentially Avoidable Hospitalizations for COPD and Pneumonia: The Role of Physician and Practice Characteristics (2007) (53)
Alternative State-Level Financing for Hepatitis C Treatment-The "Netflix Model". (2018) (52)
Gardasil: from bench, to bedside, to blunder (2010) (52)
Comorbidities, smoking status, and life expectancy among individuals eligible for lung cancer screening (2015) (51)
Radiation therapy facilities in the United States. (2006) (49)
Benchmarking lung cancer mortality rates in current and former smokers. (2004) (49)
Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending. (2017) (48)
Risk charts: putting cancer in context. (2002) (48)
Identifying and Measuring Hospital Characteristics Using the SEER-Medicare Data and Other Claims-Based Sources (2002) (47)
The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities. (2014) (46)
Physician-Driven Variation in Nonrecommended Services Among Older Adults Diagnosed With Cancer. (2016) (45)
Overuse of health care services: when less is more … more or less. (2013) (44)
Racial disparities and site of care. (2005) (43)
The first months of the prescription-drug benefit--a CMS update. (2006) (43)
Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizations. (2003) (42)
Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer. (2006) (41)
Costs of cancer care: a view from the centers for Medicare and Medicaid services. (2007) (41)
Reduced lung-cancer mortality with CT screening. (2011) (36)
The Cost of Postoperative Pancreatic Fistula Versus the Cost of Pasireotide: Results from a Prospective Randomized Trial (2017) (36)
High burden of palliative needs among older intensive care unit survivors transferred to post-acute care facilities. a single-center study. (2013) (35)
Estimating individual risk for lung cancer. (2011) (31)
Methadone dosing, heroin affordability, and the severity of addiction. (1999) (31)
A prescription for a modern Medicare program. (2005) (30)
Association of Hospital Costs With Complications Following Total Gastrectomy for Gastric Adenocarcinoma (2017) (30)
Piloting IBM Watson Oncology within Memorial Sloan Kettering’s regional network. (2014) (29)
Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle. (2019) (27)
Long-term central venous catheter use and risk of infection in older adults with cancer. (2014) (26)
Federal initiatives to support rapid learning about new technologies. (2007) (25)
Overdiagnosis in lung cancer: different perspectives, definitions, implications (2008) (23)
Impact of Infection by Vancomycin-Resistant Enterococcus on Survival and Resource Utilization for Patients With Leukemia (2002) (23)
Wide variation in payments for Medicare beneficiary oncology services suggests room for practice-level improvement. (2015) (22)
Inconsistencies in findings from the early lung cancer action project studies of lung cancer screening. (2011) (22)
ReCAP: Hospitalizations in Older Adults With Advanced Cancer: The Role of Chemotherapy. (2016) (21)
Delays in the Publication of Important Clinical Trial Findings in Oncology (2018) (21)
National Coverage Analysis of CAR-T Therapies - Policy, Evidence, and Payment. (2018) (21)
Using practice guidelines to assess cancer care quality. (2005) (20)
Medication overuse in oncology: current trends and future implications for patients and society. (2018) (20)
Copay Assistance for Expensive Drugs: A Helping Hand That Raises Costs (2016) (17)
Pem and the cost of multicycle maintenance. (2010) (17)
Do the data support the comorbidity hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial results? (2011) (17)
Quality of Cancer Surveillance Clinical Practice Guidelines: Specificity and Consistency of Recommendations (2017) (17)
Changes in the availability of screening mammography, 2000–2010 (2013) (17)
Reforming the payment system for medical oncology. (2013) (17)
Epidemiology of lung cancer. (2000) (17)
Consider saying yes. (2003) (17)
Arterial Desaturation Syndrome Following Pleurodesis with Talc Slurry: Incidence, Clinical Features, and Outcome (2003) (15)
Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir’s Value (2020) (15)
Race, Ethnicity, Health Insurance, and Mortality in Older Survivors of Critical Illness (2017) (15)
Payment Reform for Better Value and Medical Innovation (2017) (14)
Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries (2021) (14)
Low-dose CT for lung cancer screening. (2018) (14)
Cost sharing for health care--whose skin? Which game? (2008) (13)
Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs (2021) (13)
Walking the Tightrope Between Treatment Efficacy and Price. (2016) (13)
The relation between physician experience and patterns of care for patients with AIDS-related Pneumocystis carinii pneumonia: results from a survey of 1,500 physicians in the United States. (1999) (13)
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. (2014) (12)
Postmenopausal hormone therapy and breast cancer: an uncertain trade-off. (2010) (12)
Identifying Cancer-Directed Surgeries in Medicare Claims: A Validation Study Using SEER-Medicare Data. (2019) (11)
Infused chemotherapy use in the elderly after patent expiration. (2012) (11)
Review of Current Policy Strategies to Reduce US Cancer Drug Costs. (2019) (11)
Critical Choices: What Information Do Patients Want When Selecting a Hospital for Cancer Surgery? (2018) (10)
Hospital length of stay for severe COVID-19: implications for Remdesivir's value (2020) (10)
Validity of same-side reoperation after total hip and knee arthroplasty using administrative databases. (2009) (10)
Ramucirumab for Colon Cancer and the Problem of Rising Prices Independent of Benefits. (2015) (9)
Outcome-blinded peer review. (2011) (9)
Perilous potential: The chance to save lives, or lose them, through low dose computed tomography screening for lung cancer (2013) (9)
Book Review Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care Edited by Brian D. Smedley, Adrienne Y. Stith, and Alan R. Nelson. 764 pp. Washington, D.C., National Academies Press, 2003. $79.95. 0-309-08532-2 (2003) (8)
Female representation among US National Comprehensive Cancer Network guideline panel members. (2019) (8)
Raising the Bar for the U.S. Preventive Services Task Force (2014) (8)
Despite The FDA's Five-Year Plan, Black Patients Remain Inadequately Represented In Clinical Trials For Drugs. (2022) (8)
Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer. (2017) (8)
Mapping conflict of interests: scoping review (2021) (8)
Cost-effectiveness analysis of an established, effective procedure. (2009) (8)
Disenrollment from Medicare managed care among beneficiaries with and without a cancer diagnosis. (2008) (8)
Model-Based Eligibility for Lung Cancer Screening: Where Theory Meets Practice (2018) (8)
Computed Tomography Screening for Lung Cancer (2008) (7)
Preventive Services Offered in Executive Physicals at Top-Ranked Hospitals. (2019) (7)
Lung cancer screening. (2008) (7)
Provider Differences in Use of Implanted Ports in Older Adults With Cancer (2015) (7)
Untreated patients in "CT screening for lung cancer: update 2007". (2008) (7)
Smoking as a factor in causing lung cancer. (2009) (7)
Next steps for IBM Watson Oncology: Scalability to additional malignancies. (2014) (7)
The 6 Functions of Health Insurance. (2019) (7)
Understanding the Rewards of Successful Drug Development - Thinking Inside the Box. (2020) (7)
Changes in Drug List Prices and Amounts Paid by Patients and Insurers (2020) (7)
Quality Wrapped in Volume Inside a Hospital (2009) (6)
An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countries. (2018) (6)
The gender gap in critical care task force participation. (2019) (6)
Money-Back Guarantees for Expensive Drugs: Wolf's Clothing but a Sheep Underneath (2018) (6)
Practice-Changing Strategies to Deliver Affordable, High-Quality Cancer Care: Summary of an Institute of Medicine Workshop. (2013) (6)
Using Nominal Group Technique to Identify Key Attributes of Oncology Treatments for a Discrete Choice Experiment (2019) (6)
Physician's Office and Hospital Outpatient Setting in Oncology: It's About Prices, Not Use. (2017) (6)
The Prescription Drug User Fee Act (2022) (6)
Human papillomavirus vaccine coverage – Author's reply (2010) (5)
Multiplicities in the assessment of multiple vitamins: is it too soon to tell men that vitamins prevent cancer? (2012) (5)
Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors (2017) (5)
Beyond Jeopardy!: Harnessing IBM's Watson to improve oncology decision making. (2013) (5)
Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer. (2020) (5)
Hospital outpatient versus physician office cost for physician administered cancer drugs (2017) (5)
Insights into the increasing costs of cancer drugs. (2019) (4)
Cancer hospital advertising and outcomes: trust the messenger? (2019) (4)
Complications Associated With Use of Long-Term Central Venous Catheters Among Commercially Insured Women With Breast Cancer. (2015) (4)
Postmenopausal Hormone Therapy and Breast Cancer (2010) (4)
Review of current literature (2005) (4)
Outcomes after Long-Term Acute Care: An Analysis of 133 Mechanically Ventilated Patients. (1999) (4)
The Accuracy and Usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability Rating (2020) (4)
Association Between Quality of Care and the Sociodemographic Composition of Physicians’ Patient Panels: A Repeat Cross-Sectional Analysis (2011) (4)
Computed Tomography Screening for Lung Cancer—Reply (2007) (4)
Surrogate Markers and the Association of Low-Dose CT Lung Cancer Screening With Mortality (2018) (3)
Re: All-cause mortality in randomized trials of cancer screening. (2002) (3)
Trends in Female Representation on NCCN Guideline Panels. (2020) (3)
The association between drug industry payments and NCCN guideline panel membership. (2020) (3)
Visits to urologists and radiation oncologists prior to treatment decision making for clinically localized prostate cancer (LCaP) (2007) (3)
Thirty Day Resource Utilization after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies (2019) (3)
NCCN Roundtable:Value-Based Decision-Making at the Bedside. (2015) (3)
Assessment of variation in 30‐day mortality following cancer surgeries among older adults across US hospitals (2020) (3)
Practice Patterns for Older Adult Patients With Advanced Cancer: Physician Office Versus Hospital Outpatient Setting. (2019) (3)
Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer. (2021) (3)
Alternative pricing strategies for cancer drugs--reply. (2015) (3)
CT screening for lung cancer. (2007) (3)
Which Drug Prices Should Medicare Negotiate? A "Too Little" or "Too Late" Approach. (2019) (3)
Response to "CT screening for lung cancer: update 2007". (2008) (3)
Expansion of the Medicare 340B Payment Program: Hospital Participation, Prescribing Patterns and Reimbursement, and Legal Challenges. (2018) (2)
Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines. (2021) (2)
Use of PET Imaging: Another Non-Biological Source of Racial Disparities in US Cancer Care. (2020) (2)
Identifying providers of care to individuals with human immunodeficiency virus for a mail survey using a prescription tracking database. (1999) (2)
Computed Tomography Screening for Lung Cancer (2013) (2)
Assessing whether cancer stage is needed to evaluate measures of hospital surgical performance. (2019) (2)
Re: Risk Charts: Putting Cancer in Context (2002) (2)
Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines. (2021) (2)
Association Between Clinical Value and Financial Cost of Cancer Treatments: A Cross-Sectional Analysis. (2020) (2)
Improving quality and addressing the rising costs of cancer care: two birds, one stone. (2011) (2)
Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014-2017. (2021) (2)
Lung Cancer Screening Guidelines Updated (2012) (2)
The impact of chemotherapy on hospitalizations and emergency care in older adults with advanced cancer. (2015) (2)
Do surgical quality gaps cause healthcare disparities? (2008) (2)
Predictors Of 6 Month Mortality For Elderly Survivors Of Critical Illness (2012) (1)
JAMA Peer Reviewers in 2019. (2020) (1)
The value of cancer treatments: Patient and clinician perspectives. (2017) (1)
Visions of hope in cancer: focus on infrastructure: comment on "characteristics of oncology clinical trials" and "toward accountable cancer care". (2013) (1)
Identifying Attributes of Cancer Treatments: What Do Stakeholders Consider Important? (2017) (1)
Impact of Routine Radiographic Surveillance After Complete Resection of Lung Cance (2003) (1)
Reviewers for the Journal, January-June 2016. (2016) (1)
Should the American Society of Clinical Oncology Ask for Peer Review Before Publishing Its Advocacy Research? (2016) (1)
Infused chemotherapy use in the elderly after patent expiration. (2012) (1)
Computed Tomographic Screening for Lung Cancer—Reply (2012) (1)
JAMA Peer Reviewers in 2020. (2021) (1)
Evaluation of Use of Shorter Radiation Regimens for Breast and Prostate Cancer in the US, 2015-2017 (2020) (1)
Real-world effectiveness of approved anticancer agents among Medicare beneficiaries. (2019) (1)
Enhancing the Value of the ASCO Value Framework (2018) (1)
Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation (2022) (1)
Health Returns to Pharmaceutical Innovation in the Market for Oral Chemotherapy in Response to Insurance Coverage Expansion (2017) (1)
JAMA Peer Reviewers in 2018. (2019) (1)
The correlation between clinical benefit and financial cost of cancer drugs. (2020) (1)
Industry Payments to Physicians are Kickbacks. How Should Stakeholders Respond? (2022) (1)
Cancer survival in the context of growing hospital participation in Medicare ACOs. (2018) (1)
Resource Utilization Early after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies (2018) (1)
Baseline demographics and disparities in cancer registration trials: An analysis of U.S. Food and Drug Administration approved drugs in 2015 and 2016. (2018) (1)
Resurrecting treatment histories of dead patients. Authors' reply (2005) (1)
Estimating hospitals’ all-payer volume of cancer surgeries from Fee-for-Service Medicare claims (2020) (1)
Commentary on Hsiue et al: Cost savings and data limitations of new cancer drug studies (2020) (1)
1079-81 Preoperative risk factors for post-coronary artery bypass graft atrial fibrillation (2004) (1)
Pharmaceutical industry payments to physicians for the promotion of cancer drugs. (2022) (0)
Use of bone modifying agents for metastatic castrate-resistant prostate cancer. (2022) (0)
Financial payments from the pharmaceutical industry to U.S. cancer centers, 2014-2019. (2022) (0)
Long-term central venous catheters and infections in older adults with cancer. (2013) (0)
Physician-driven variation in non-recommended imaging for women with early stage breast cancer. (2015) (0)
Disenrollment from Medicare managed care: Does a cancer diagnosis make a difference? (2008) (0)
Improving outpatient oncology practice: several steps into a long journey. (2014) (0)
Financial conflicts of interest at three prominent oncology clinical pathway vendors. (2017) (0)
Survival in women after diagnosis of lung cancer. (2007) (0)
Ms. Thompson's murmur. (1992) (0)
Thanks to reviewers in 2010 (2010) (0)
Review of current literature (1903) (0)
Outcomes for patients with advanced epithelial ovarian cancer treated with adjuvant chemotherapy at a regional network facility compared to the central campus (2015) (0)
JAMA Peer Reviewers in 2004 (2016) (0)
JAMA Internal Medicine Peer Reviewers in 2017. (2018) (0)
High hospital volume is associated with more consistent long-term mortality rates (2021) (0)
CT screening for lung cancer. (2007) (0)
Use of bone modifying agents in patients with metastatic castrate-sensitive prostate cancer. (2021) (0)
Linking Drug Costs to Their Benefits: Value-Based Drug Pricing (2017) (0)
Thanks to Reviewers2017 (2017) (0)
JAMA Peer Reviewers in 2018. (2019) (0)
Opportunity for performance measurement: 30-day mortality following cancer surgeries across U.S. hospitals. (2019) (0)
JAMA Peer Reviewers for 2003 (2017) (0)
and Mortality in Postmenopausal Women Estrogen Plus Progestin and Breast Cancer Incidence (2010) (0)
Definition of a Beneficial Screening Test (2009) (0)
Slide Presentations: Sunday, October 23, 2011 | October 2011A Prognostic Model for 6-Month Mortality in Elderly Survivors of Critical Illness (2011) (0)
PCN404 HOW DO NEW ONCOLOGY VALUE ASSESSMENT FRAMEWORKS COMPARE TO THE QALY? (2019) (0)
Compulsory Licensing of Pharmaceuticals in High-Income Countries: A Comparative Analysis. (2022) (0)
Lung Cancer Screening: Response (2013) (0)
Review of current literature (1934) (0)
Thanks to authors and peer reviewers (2007) (0)
Reviewers for the Journal, July-December 2017. (2019) (0)
Distribution of Predictable Risk for Lung Cancer: Use of a Lung Cancer Prediction Too (2003) (0)
Commentary: Medicare's 2006 Oncology Demonstration Project: Lost in Translation? (2010) (0)
Perspectives o n t he V alue o f A merican S ociety o f C linical Oncology C linical G uidelines a s R eported b y O ncologists a nd Health M aintenance O rganizations (2003) (0)
Defining Value-Based Pricing of Drugs-Reply. (2018) (0)
A conundrum in cancer quality measurement: Performance on long-term survival reflects performance a long time ago. (2019) (0)
Computed tomography screening for lung cancer. Authors' reply (2007) (0)
Global Reimbursement: The Authors Reply (2011) (0)
But Will They Trade Health? Developing An Economic Value Framework for Oncology (2017) (0)
Medicare Drug Benefit: A Beneficial Side Effect of the Medicare Drug Benefit (2005) (0)
CR4 RESOURCE UTILIZATION WITHIN 30 DAYS OF CAR T CELLS FOR HEMATOLOGIC MALIGNANCIES (2019) (0)
Thanks to Reviewers2014 (2014) (0)
Adjuvant C hemotherapy U se f or M edicare B eneficiaries With S tage I I C olon C ancer (2002) (0)
Using Comparative Effectiveness: The Authors Reply (2011) (0)
Will Shifts in Oncology Outpatient Points of Care Lead to More Profits or Savings (2014) (0)
linical Prediction Rule for Atrial Fibrillation fter Coronary Artery Bypass Grafting (2016) (0)
Physicians' experience and survival in patients with AIDS. (1996) (0)
Perilous Potential: Screening for Lung Cancer (2014) (0)
Long-term central venous catheter use among cancer patients in administrative claims data. (2012) (0)
The Zigzagging zeitgeist of health services research: Rapidly changing priorities in the field. (2014) (0)
Who G ets A djuvant T reatment f or S tage I I a nd I II R ectal Cancer? I nsight F rom S urveillance, E pidemiology, a nd E nd Results-Medicare (2001) (0)
Use of Postoperative Radiotherapy (PORT) for Resectable Non-Small Cell Lung Cancer (NSCLC) (2005) (0)
Provider volume and guideline compliance in ovarian cancer patients receiving front-line chemotherapy (2018) (0)
Thanks to Reviewers—2020 (2020) (0)
Review of current literature (1903) (0)
Resurrecting Treatment Histories of Dead Patients—Reply (2005) (0)
Addressing Challenges in Lung Cancer Screening (2013) (0)
Identifying sexual orientation in the medical record: A first step towards understanding gynecologic cancer disparities. (2018) (0)
Ethical and human subject burdens of trials conducted to evaluate biosimilars (2021) (0)
Adjuvant Anthracyclines and Taxanes: Quantifying the Costs of Therapeutic Advances in Breast Cancer (2009) (0)
Response: Re: Inconsistencies in Findings from the Early Lung Cancer Action Project Studies of Lung Cancer Screening (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Peter Brian Bach?

Peter Brian Bach is affiliated with the following schools:

Medical University of South Carolina
University of California, Los Angeles
Massachusetts Institute of Technology
University of Chicago
New York University

Peter Brian Bach's Academic­Influence.com Rankings

Why Is Peter Brian Bach Influential?

Peter Brian Bach's Published Works

Published Works

What Schools Are Affiliated With Peter Brian Bach?

Peter Brian Bach's AcademicInfluence.com Rankings